| 000 | 01515 a2200421 4500 | ||
|---|---|---|---|
| 005 | 20250517210233.0 | ||
| 264 | 0 | _c20190128 | |
| 008 | 201901s 0 0 eng d | ||
| 022 | _a1940-6029 | ||
| 024 | 7 |
_a10.1007/978-1-4939-7734-5_11 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aSubasinghe, Duminda | |
| 245 | 0 | 0 |
_aPredictive Marker: HER2 in Esophageal Adenocarcinoma. _h[electronic resource] |
| 260 |
_bMethods in molecular biology (Clifton, N.J.) _c2018 |
||
| 300 |
_a119-134 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 |
_aAdenocarcinoma _xpathology |
| 650 | 0 | 4 |
_aAntineoplastic Agents _xpharmacology |
| 650 | 0 | 4 | _aBiopsy |
| 650 | 0 | 4 |
_aChemotherapy, Adjuvant _xmethods |
| 650 | 0 | 4 |
_aEsophageal Neoplasms _xpathology |
| 650 | 0 | 4 | _aEsophagoscopy |
| 650 | 0 | 4 |
_aEsophagus _xpathology |
| 650 | 0 | 4 | _aFalse Negative Reactions |
| 650 | 0 | 4 | _aFalse Positive Reactions |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aImmunohistochemistry _xinstrumentation |
| 650 | 0 | 4 |
_aIn Situ Hybridization _xinstrumentation |
| 650 | 0 | 4 |
_aMolecular Targeted Therapy _xmethods |
| 650 | 0 | 4 | _aPatient Selection |
| 650 | 0 | 4 |
_aReceptor, ErbB-2 _xanalysis |
| 650 | 0 | 4 |
_aTissue Fixation _xinstrumentation |
| 650 | 0 | 4 | _aTreatment Outcome |
| 700 | 1 | _aAcott, Nathan | |
| 700 | 1 | _aKumarasinghe, M Priyanthi | |
| 773 | 0 |
_tMethods in molecular biology (Clifton, N.J.) _gvol. 1756 _gp. 119-134 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1007/978-1-4939-7734-5_11 _zAvailable from publisher's website |
| 999 |
_c28233504 _d28233504 |
||